Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by CHARLOTTE C SUN and LARISSA ALEJANDRA MEYER.
CHARLOTTE C SUN
Connection Strength
5.362
LARISSA ALEJANDRA MEYER
  1. Determination of quality of life-related health utilities for surgical complications in ovarian cancer. Gynecol Oncol. 2024 Feb 19; 185:101-107.
    View in: PubMed
    Score: 0.244
  2. Secondary validation of an ovarian cancer-specific comorbidity index in a US population. Int J Gynecol Cancer. 2023 05 01; 33(5):749-754.
    View in: PubMed
    Score: 0.231
  3. Predicting 180-day mortality for women with ovarian cancer using machine learning and patient-reported outcome data. Sci Rep. 2022 12 08; 12(1):21269.
    View in: PubMed
    Score: 0.224
  4. Medicaid Expansion and Postoperative Mortality in Women with Gynecologic Cancer: A Difference-in-Difference Analysis. Ann Surg Oncol. 2023 Mar; 30(3):1508-1519.
    View in: PubMed
    Score: 0.223
  5. Association between time to diagnosis, time to treatment, and ovarian cancer survival in the United States. Int J Gynecol Cancer. 2022 09 06; 32(9):1153-1163.
    View in: PubMed
    Score: 0.221
  6. Temporal trends of healthcare system use between symptomatic presentation and ovarian cancer diagnosis in the United States. Int J Gynecol Cancer. 2022 07 04; 32(7):899-905.
    View in: PubMed
    Score: 0.218
  7. Medicaid expansion and 2-year survival in women with gynecologic cancer: a difference-in-difference analysis. Am J Obstet Gynecol. 2022 09; 227(3):482.e1-482.e15.
    View in: PubMed
    Score: 0.215
  8. Algorithm to Identify Incident Epithelial Ovarian Cancer Cases Using Claims Data. JCO Clin Cancer Inform. 2022 03; 6:e2100187.
    View in: PubMed
    Score: 0.213
  9. Factors impacting the time to ovarian cancer diagnosis based on classic symptom presentation in the United States. Cancer. 2021 Nov 15; 127(22):4151-4160.
    View in: PubMed
    Score: 0.205
  10. Patient cost sharing during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment in ovarian cancer. Am J Obstet Gynecol. 2021 07; 225(1):68.e1-68.e11.
    View in: PubMed
    Score: 0.198
  11. Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer. Gynecol Oncol. 2021 04; 161(1):56-62.
    View in: PubMed
    Score: 0.197
  12. National trends in bowel and upper abdominal procedures in ovarian cancer surgery. Int J Gynecol Cancer. 2020 08; 30(8):1195-1202.
    View in: PubMed
    Score: 0.190
  13. Body mass index and attitudes towards health behaviors among women with endometrial cancer before and after treatment. Int J Gynecol Cancer. 2020 02; 30(2):187-192.
    View in: PubMed
    Score: 0.183
  14. Centers for Medicare and Medicaid Services' Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) scores and gynecologic oncology surgical outcomes. Gynecol Oncol. 2019 08; 154(2):405-410.
    View in: PubMed
    Score: 0.176
  15. National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer or atypical hyperplasia. Am J Obstet Gynecol. 2019 11; 221(5):474.e1-474.e11.
    View in: PubMed
    Score: 0.176
  16. Total and out-of-pocket costs of different primary management strategies in ovarian cancer. Am J Obstet Gynecol. 2019 08; 221(2):136.e1-136.e9.
    View in: PubMed
    Score: 0.174
  17. National trends, outcomes, and costs of radiation therapy in the management of low- and high-intermediate risk endometrial cancer. Gynecol Oncol. 2019 03; 152(3):439-444.
    View in: PubMed
    Score: 0.173
  18. Comparison of patient reported symptom burden on an enhanced recovery after surgery (ERAS) care pathway in patients with ovarian cancer undergoing primary vs. interval tumor reductive surgery. Gynecol Oncol. 2019 03; 152(3):501-508.
    View in: PubMed
    Score: 0.173
  19. Women's preferences for cancer risk management strategies in Lynch syndrome. Gynecol Oncol. 2019 03; 152(3):514-521.
    View in: PubMed
    Score: 0.173
  20. Disparities in treatment and survival among elderly ovarian cancer patients. Gynecol Oncol. 2018 11; 151(2):269-274.
    View in: PubMed
    Score: 0.168
  21. Three Lymphadenectomy Strategies in Low-Risk Endometrial Carcinoma: A Cost-Effectiveness Analysis. Obstet Gynecol. 2018 07; 132(1):52-58.
    View in: PubMed
    Score: 0.165
  22. Neoadjuvant chemotherapy in elderly women with ovarian cancer: Rates of use and effectiveness. Gynecol Oncol. 2018 09; 150(3):451-459.
    View in: PubMed
    Score: 0.165
  23. Impact of body mass index and operative approach on surgical morbidity and costs in women with endometrial carcinoma and hyperplasia. Gynecol Oncol. 2017 04; 145(1):55-60.
    View in: PubMed
    Score: 0.150
  24. Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer. J Clin Oncol. 2016 11 10; 34(32):3854-3863.
    View in: PubMed
    Score: 0.147
  25. The management of malignant ascites and impact on quality of life outcomes in women with ovarian cancer. Expert Rev Qual Life Cancer Care. 2016; 1(3):231-238.
    View in: PubMed
    Score: 0.143
  26. Avoidable tragedies: Disparities in healthcare access among medically underserved women diagnosed with cervical cancer. Gynecol Oncol. 2015 Dec; 139(3):500-5.
    View in: PubMed
    Score: 0.137
  27. Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer. Cancer. 2024 04 01; 130(7):1061-1071.
    View in: PubMed
    Score: 0.060
  28. Impacts of Medicaid Expansion on Stage at Cancer Diagnosis by Patient Insurance Type. Am J Prev Med. 2022 Dec; 63(6):915-925.
    View in: PubMed
    Score: 0.055
  29. Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clin Cancer Res. 2021 12 01; 27(23):6354-6365.
    View in: PubMed
    Score: 0.052
  30. Prospective assessment of patient-reported outcomes in gynecologic cancer patients before and after pelvic exenteration. Gynecol Oncol. 2018 06; 149(3):484-490.
    View in: PubMed
    Score: 0.041
  31. Perirenal Adiposity is Associated With Lower Progression-Free Survival From Ovarian Cancer. Int J Gynecol Cancer. 2018 02; 28(2):285-292.
    View in: PubMed
    Score: 0.040
  32. Treatment Patterns, Outcomes, and Costs for Bowel Obstruction in Ovarian Cancer. Int J Gynecol Cancer. 2017 09; 27(7):1350-1359.
    View in: PubMed
    Score: 0.039
  33. Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer. JAMA Oncol. 2016 Nov 01; 2(11):1427-1433.
    View in: PubMed
    Score: 0.037
  34. The DISINFECT Initiative: Decreasing the Incidence of Surgical INFECTions in Gynecologic Oncology. Ann Surg Oncol. 2017 Feb; 24(2):362-368.
    View in: PubMed
    Score: 0.036
  35. Retrospective review of symptoms and palliative care interventions in women with advanced cervical cancer. Gynecol Oncol. 2015 Dec; 139(3):553-8.
    View in: PubMed
    Score: 0.034
  36. Survivors of gynecologic malignancies: impact of treatment on health and well-being. J Cancer Surviv. 2016 Apr; 10(2):261-70.
    View in: PubMed
    Score: 0.034
  37. Improvement in quality of life after robotic surgery results in patient satisfaction. Gynecol Oncol. 2015 Sep; 138(3):727-30.
    View in: PubMed
    Score: 0.034
  38. Survival after intestinal perforation: can it be predicted? Gynecol Oncol. 2009 Dec; 115(3):349-53.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.